Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Martek Biosciences Corp. (“Martek” or the “Company”) (NasdaqGS: MATK) concerning its potential acquisition by Royal DSM N.V. (“Royal”). Under the terms of the offer, Martek shareholders will receive $31.50 in cash for each share of Royal common stock owned for a total transaction value of approximately $1.09 billion.
The investigation is focused on the potential unfairness of the deal price to Martek’s shareholders, the process by which Martek’s directors considered the transaction, and potential conflicts of interests on the part of Martek Board members. Martek’s recently announced fourth quarter results showed revenue growth and significant operational improvements.
If you are interested in discussing your rights as Martek shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050 or by email at
Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in financial litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers.
To learn more about Finkelstein Thompson LLP, please visit our web site at
. Attorney advertising. Prior results do not guarantee similar outcomes.